Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
It is of interest how ezetimibe alone or in combination with statin may influence atherogenic
dense Low Density Lipoprotein (dLDL) in patients with type 2 diabetes mellitus. The primary
objective of this study will be whether there is a change of the concentrations of
Apolipoprotein B (ApoB) in dLDL from baseline in each of the 3 treatment groups.